Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305396 · ClinicalTrials.gov registry record · Phase 4
Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
A Phase 4 study of Kidney Transplantation, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00305396: Completed Phase 4 study of Kidney Transplantation, sponsored by Vanderbilt University.
NCT00305396 is a Phase 4 study of Kidney Transplantation that has completed, run by Vanderbilt University. The registered enrollment target is 80 participants, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305396, a Phase 4 study of Kidney Transplantation, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, single center, open-label, randomized trial of Thymoglobulin induction and sirolimus, prednisone, and mycophenolate mofetil versus Thymoglobulin induction and tacrolimus, prednisone, and mycophenolate mofetil in non-HLA identical living or deceased donor kidney transplant recipients.
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center/Nashville VA - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-03 |
| Phase | Phase 4 |
What the finished NCT00305396 record still lists
NCT00305396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT00305396 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00305396 about?
NCT00305396 is a clinical study titled "Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation". A prospective, single center, open-label, randomized trial of Thymoglobulin induction and sirolimus, prednisone, and mycophenolate mofetil versus Thymoglobulin induction and tacrolimus, prednisone, and mycophenolate mofetil in non-HLA identical living or deceased donor kidney transplant recipients.
What is the current status of trial NCT00305396?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2004-04. Estimated completion is 2005-03.
What conditions does trial NCT00305396 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT00305396?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT00305396?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305396 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00305396's enrollment target sits among peer trials
80 19th of 33 higher than 15 of 33 other Kidney Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Envarsus XR® in Adolescent Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
COMPLETED · Phase 4
-
Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
COMPLETED · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Prehabilitation for Kidney Transplant Candidates
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia